As more biosimilars are earning regulatory approvals in both the United States and the European Union, the question of whether to switch patients (and at what point to do so) continues to be discussed; researchers will present findings from 2 etanercept switching studies in patients with rheumatoid arthritis (RA) during the American College of Rheumatology’s (ACR) Annual meeting, held in Chicago, Illinois October 19-24, 2018.
As more biosimilars are earning regulatory approvals in both the United States and the European Union, the question of whether to switch patients (and at what point to do so) continues to be discussed; researchers will present findings from 2 etanercept switching studies in patients with rheumatoid arthritis (RA) during the American College of Rheumatology’s (ACRs) Annual meeting, held in Chicago, Illinois October 19-24, 2018.
The first study1, a single-center retrospective observational study, analyzed findings from when patients with RA were switched from the reference Enbrel to the biosimilar sold as Benepali at Blackpool Teaching Hospitals located in the United Kingdom. The review included all patients switched from July 2016 to April 2018.
In total, 72 patients were switched to the biosimilar, of whom 19 (26.4%) switched back to the reference product after 6 months. All 19 of these patients remained on the reference product until the time of data analysis, which was a follow up period of 12 months.
Researchers found that the reasons for withdrawal were loss of efficacy (58%), adverse events (AEs) (32%), infection (5%) and difficulty using the device to administer the medication (5%). However, the majority of patients that who switched to the biosimilar had a good response (73.6%), which the authors note is in keeping with the current evidence.
In another switching study2, researchers compared the efficacy and safety of a proposed etanercept biosimilar, GP2015, with the reference product and evaluated the effects of switching from the reference to the biosimilar in patients with moderate to severe RA.
EQUIRA, a 48-week, randomized, double-blind, phase 3 confirmatory study had a primary endpoint of equivalent change from baseline as measured by disease activity score in a count of 28 joints with C-reactive protein (DAS28-CRP) at week 24. Patients 18 years or older with active RA who had an inadequate response to methotrexate were randomized 1:1 to receive 50 mg of GP2015 or the reference product subcutaneously once-weekly for 24 weeks.
The study enrolled 186 patients to the GP2015 arm, and 190 patients to the reference arm. Baseline characteristics were comparable between the groups, and the primary endpoint for equivalence during the first 24 weeks (defined as treatment period 1) was met. Additionally, at week 48, the American College of Rheumatology 20% improvement (ACR20) response rates were comparable between patients who continued on or switched to the biosimilar.
At week 24, patients with moderate European League Against Rheumatism (EULAR) response either continued the biosimilar or were switched to receive 50 mg of GP2015 for up to 48 weeks. During this time period (defined as treatment period 2) AEs occurred in 42.9% of patients in the biosimilar arm versus 38% of patients in the reference arm, respectively; however, only 13.1% versus 11.4% were considered drug-related.
Overall, the efficacy of GP2015 over 48 weeks was found to be comparable to that of the reference product. The researchers also noted that the switch from the reference to the biosimilar did not impact the efficacy or safety of etanercept treatment in patients with moderate to severe RA.
References
1. Madenidou AV, Jeffries A, Varughese S, et al. Switching patients with arthritis from etanercept (Enbrel) to the biosimilar drug, Benepali: a single-center retrospective observational study. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 2533. https://acrabstracts.org/abstract/switching-patients-with-arthritis-from-etanercept-enbrel-to-the-biosimilar-drug-benepali-a-single-center-retrospective-observational-study/.
2. Kavanaugh A, Mattucci-Cerini M, Schulze-Koop H, et al. Phase 3 Equirea 48-week study results demonstrated no impact on efficacy and safety when patients with moderate-to-severe rheumatoid arthritis were switched between reference etanercept (ETN) and GP2015, an etanercept biosimlar. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 2250. https://acrabstracts.org/abstract/phase-3-equira-48-week-study-results-demonstrated-no-impact-on-efficacy-and-safety-when-patients-with-moderate-to-severe-rheumatoid-arthritis-were-switched-between-reference-etanercept-etn-and-gp201/.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.